Last reviewed · How we verify
Disease caused by rickettsiae — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vibramycin | doxycycline | Generic (originally Pfizer) | Tetracycline antibiotic | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 | 1967-01-01 | |
| Chlorocidin | CHLORAMPHENICOL | Parkedale | Amphenicol-class Antibacterial | Cytochrome P450 3A4 | 1950-01-01 | |
| Doxycyclin | Doxycyclin | Bulovka Hospital | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Disease caused by rickettsiae
- Bulovka Hospital · 1 drug in Disease caused by rickettsiae
- Generic (originally Pfizer) · 1 drug in Disease caused by rickettsiae
- Parkedale · 1 drug in Disease caused by rickettsiae
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Disease caused by rickettsiae:
- Disease caused by rickettsiae treatment updates — RSS
- Disease caused by rickettsiae treatment updates — Atom
- Disease caused by rickettsiae treatment updates — JSON
Cite this brief
Drug Landscape (2026). Disease caused by rickettsiae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disease-caused-by-rickettsiae. Accessed 2026-06-10.
Related
- Disease caused by rickettsiae full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing